121 related articles for article (PubMed ID: 11262189)
21. Urokinase type plasminogen activator receptor is involved in insulin-like growth factor-induced migration of rhabdomyosarcoma cells in vitro.
Gallicchio MA; Kaun C; Wojta J; Binder B; Bach LA
J Cell Physiol; 2003 Oct; 197(1):131-8. PubMed ID: 12942549
[TBL] [Abstract][Full Text] [Related]
22. High urokinase expression contributes to the angiogenic properties of endothelial cells derived from circulating progenitors.
Basire A; Sabatier F; Ravet S; Lamy E; Mialhe A; Zabouo G; Paul P; Gurewich V; Sampol J; Dignat-George F
Thromb Haemost; 2006 Apr; 95(4):678-88. PubMed ID: 16601839
[TBL] [Abstract][Full Text] [Related]
23. Wound-induced migration of MDA-MB-435 and SKOV-3 cancer cells is regulated by plasminogen activator inhibitor-1.
Whitley BR; Church FC
Int J Oncol; 2005 Sep; 27(3):749-57. PubMed ID: 16077925
[TBL] [Abstract][Full Text] [Related]
24. Airway epithelial cell migration dynamics. MMP-9 role in cell-extracellular matrix remodeling.
Legrand C; Gilles C; Zahm JM; Polette M; Buisson AC; Kaplan H; Birembaut P; Tournier JM
J Cell Biol; 1999 Jul; 146(2):517-29. PubMed ID: 10427102
[TBL] [Abstract][Full Text] [Related]
25. Montelukast regulates eosinophil protease activity through a leukotriene-independent mechanism.
Langlois A; Ferland C; Tremblay GM; Laviolette M
J Allergy Clin Immunol; 2006 Jul; 118(1):113-9. PubMed ID: 16815146
[TBL] [Abstract][Full Text] [Related]
26. Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity.
Stillfried GE; Saunders DN; Ranson M
Breast Cancer Res; 2007; 9(1):R14. PubMed ID: 17257442
[TBL] [Abstract][Full Text] [Related]
27. Plasmin activates pro-matrix metalloproteinase-2 with a membrane-type 1 matrix metalloproteinase-dependent mechanism.
Monea S; Lehti K; Keski-Oja J; Mignatti P
J Cell Physiol; 2002 Aug; 192(2):160-70. PubMed ID: 12115722
[TBL] [Abstract][Full Text] [Related]
28. Inhibitory role of eosinophils on cell surface plasmin generation by bronchial epithelial cells: inhibitory effects of transforming growth factor beta.
Hara K; Hasegawa T; Ooi H; Koya T; Tanabe Y; Tsukada H; Igarashi K; Suzuki E; Arakawa M; Gejyo F
Lung; 2001; 179(1):9-20. PubMed ID: 11479690
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of urinary plasminogen activator, its receptor, matrix metalloproteinase-9, and von Willebrand factor in pancreatic cancer.
Harvey SR; Hurd TC; Markus G; Martinick MI; Penetrante RM; Tan D; Venkataraman P; DeSouza N; Sait SN; Driscoll DL; Gibbs JF
Clin Cancer Res; 2003 Oct; 9(13):4935-43. PubMed ID: 14581368
[TBL] [Abstract][Full Text] [Related]
30. No activation of urokinase plasminogen activator by anti-desmoglein 3 monoclonal IgG antibodies in cultured human keratinocytes.
Yamamoto Y; Aoyama Y; Shu E; Tsunoda K; Amagai M; Kitajima Y
J Dermatol Sci; 2007 Aug; 47(2):119-25. PubMed ID: 17532189
[TBL] [Abstract][Full Text] [Related]
31. Gonadotropin-releasing hormone promotes ovarian cancer cell invasiveness through c-Jun NH2-terminal kinase-mediated activation of matrix metalloproteinase (MMP)-2 and MMP-9.
Cheung LW; Leung PC; Wong AS
Cancer Res; 2006 Nov; 66(22):10902-10. PubMed ID: 17108127
[TBL] [Abstract][Full Text] [Related]
32. Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: inhibitory effects on receptor-mediated uPA activity in vitro and in vivo.
Pass J; Jögi A; Lund IK; Rønø B; Rasch MG; Gårdsvoll H; Lund LR; Ploug M; Rømer J; Danø K; Høyer-Hansen G
Thromb Haemost; 2007 Jun; 97(6):1013-22. PubMed ID: 17549305
[TBL] [Abstract][Full Text] [Related]
33. Expression of serine proteases and metalloproteinases in human pituitary adenomas and anterior pituitary lobe tissue.
Knappe UJ; Hagel C; Lisboa BW; Wilczak W; Lüdecke DK; Saeger W
Acta Neuropathol; 2003 Nov; 106(5):471-8. PubMed ID: 12904990
[TBL] [Abstract][Full Text] [Related]
34. Intestinal transformation results in transforming growth factor-beta-dependent alteration in tumor cell-cell matrix interactions.
Berger DH; O'Mahony CA; Sheng H; Shao J; Albo D; DuBois RN; Beauchamp RD
Surgery; 2003 May; 133(5):568-79. PubMed ID: 12773985
[TBL] [Abstract][Full Text] [Related]
35. Urokinase-type plasminogen activator induces BV-2 microglial cell migration through activation of matrix metalloproteinase-9.
Shin SM; Cho KS; Choi MS; Lee SH; Han SH; Kang YS; Kim HJ; Cheong JH; Shin CY; Ko KH
Neurochem Res; 2010 Jul; 35(7):976-85. PubMed ID: 20177776
[TBL] [Abstract][Full Text] [Related]
36. Arsenic trioxide (As2O3) inhibits invasion of HT1080 human fibrosarcoma cells: role of nuclear factor-kappaB and reactive oxygen species.
Park MJ; Lee JY; Kwak HJ; Park CM; Lee HC; Woo SH; Jin HO; Han CJ; An S; Lee SH; Chung HY; Park IC; Hong SI; Rhee CH
J Cell Biochem; 2005 Aug; 95(5):955-69. PubMed ID: 15962302
[TBL] [Abstract][Full Text] [Related]
37. Wound repair-induced expression of a stromelysins is associated with the acquisition of a mesenchymal phenotype in human respiratory epithelial cells.
Buisson AC; Gilles C; Polette M; Zahm JM; Birembaut P; Tournier JM
Lab Invest; 1996 Mar; 74(3):658-69. PubMed ID: 8600317
[TBL] [Abstract][Full Text] [Related]
38. Activation of pro-uPA is critical for initial escape from the primary tumor and hematogenous dissemination of human carcinoma cells.
Bekes EM; Deryugina EI; Kupriyanova TA; Zajac E; Botkjaer KA; Andreasen PA; Quigley JP
Neoplasia; 2011 Sep; 13(9):806-21. PubMed ID: 21969814
[TBL] [Abstract][Full Text] [Related]
39. Urokinase plasminogen activator released by alveolar epithelial cells modulates alveolar epithelial repair in vitro.
Van Leer C; Stutz M; Haeberli A; Geiser T
Thromb Haemost; 2005 Dec; 94(6):1257-64. PubMed ID: 16411403
[TBL] [Abstract][Full Text] [Related]
40. Alendronate promotes plasmin-mediated MMP-9 inactivation by exposing cryptic plasmin degradation sites within the MMP-9 catalytic domain.
Farina AR; Cappabianca L; Di Ianni N; Ruggeri P; Ragone M; Merolle S; Gulino A; Mackay AR
FEBS Lett; 2012 Jul; 586(16):2366-74. PubMed ID: 22677171
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
